Literature DB >> 23716562

CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features.

Bettina Bisig1, Aurélien de Reyniès, Christophe Bonnet, Pierre Sujobert, David S Rickman, Teresa Marafioti, Georges Delsol, Laurence Lamant, Philippe Gaulard, Laurence de Leval.   

Abstract

Peripheral T-cell lymphoma, not otherwise specified is a heterogeneous group of aggressive neoplasms with indistinct borders. By gene expression profiling we previously reported unsupervised clusters of peripheral T-cell lymphomas, not otherwise specified correlating with CD30 expression. In this work we extended the analysis of peripheral T-cell lymphoma molecular profiles to prototypical CD30(+) peripheral T-cell lymphomas (anaplastic large cell lymphomas), and validated mRNA expression profiles at the protein level. Existing transcriptomic datasets from peripheral T-cell lymphomas, not otherwise specified and anaplastic large cell lymphomas were reanalyzed. Twenty-one markers were selected for immunohistochemical validation on 80 peripheral T-cell lymphoma samples (not otherwise specified, CD30(+) and CD30(-); anaplastic large cell lymphomas, ALK(+) and ALK(-)), and differences between subgroups were assessed. Clinical follow-up was recorded. Compared to CD30(-) tumors, CD30(+) peripheral T-cell lymphomas, not otherwise specified were significantly enriched in ALK(-) anaplastic large cell lymphoma-related genes. By immunohistochemistry, CD30(+) peripheral T-cell lymphomas, not otherwise specified differed significantly from CD30(-) samples [down-regulated expression of T-cell receptor-associated proximal tyrosine kinases (Lck, Fyn, Itk) and of proteins involved in T-cell differentiation/activation (CD69, ICOS, CD52, NFATc2); upregulation of JunB and MUM1], while overlapping with anaplastic large cell lymphomas. CD30(-) peripheral T-cell lymphomas, not otherwise specified tended to have an inferior clinical outcome compared to the CD30(+) subgroups. In conclusion, we show molecular and phenotypic features common to CD30(+) peripheral T-cell lymphomas, and significant differences between CD30(-) and CD30(+) peripheral T-cell lymphomas, not otherwise specified, suggesting that CD30 expression might delineate two biologically distinct subgroups.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23716562      PMCID: PMC3729906          DOI: 10.3324/haematol.2012.081935

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  33 in total

1.  Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project.

Authors:  Dennis D Weisenburger; Kerry J Savage; Nancy Lee Harris; Randy D Gascoyne; Elaine S Jaffe; Kenneth A MacLennan; Thomas Rüdiger; Stefano Pileri; Shigeo Nakamura; Bharat Nathwani; Elias Campo; Francoise Berger; Bertrand Coiffier; Won-Seog Kim; Harald Holte; Massimo Federico; Wing Y Au; Kensei Tobinai; James O Armitage; Julie M Vose
Journal:  Blood       Date:  2011-01-26       Impact factor: 22.113

Review 2.  CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.

Authors:  H Stein; H D Foss; H Dürkop; T Marafioti; G Delsol; K Pulford; S Pileri; B Falini
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

3.  CD30+ lymphoproliferative disorders.

Authors:  Laurence de Leval; Philippe Gaulard
Journal:  Haematologica       Date:  2010-10       Impact factor: 9.941

Review 4.  Brentuximab vedotin for the treatment of CD30+ lymphomas.

Authors:  Kelley V Foyil; Nancy L Bartlett
Journal:  Immunotherapy       Date:  2011-04       Impact factor: 4.196

5.  Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms.

Authors:  Roberto Piva; Luca Agnelli; Elisa Pellegrino; Katia Todoerti; Valentina Grosso; Ilaria Tamagno; Alessandro Fornari; Barbara Martinoglio; Enzo Medico; Alberto Zamò; Fabio Facchetti; Maurilio Ponzoni; Eva Geissinger; Andreas Rosenwald; Hans Konrad Müller-Hermelink; Christiane De Wolf-Peeters; Pier Paolo Piccaluga; Stefano Pileri; Antonino Neri; Giorgio Inghirami
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

6.  Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations.

Authors:  Eva Geissinger; Petra Sadler; Sabine Roth; Tina Grieb; Bernhard Puppe; Nora Müller; Peter Reimer; Claudia S Vetter-Kauczok; Jörg Wenzel; Irina Bonzheim; Thomas Rüdiger; Hans Konrad Müller-Hermelink; Andreas Rosenwald
Journal:  Haematologica       Date:  2010-05-29       Impact factor: 9.941

7.  Peripheral T-cell lymphomas expressing CD30 and CD15.

Authors:  Todd S Barry; Elaine S Jaffe; Lynn Sorbara; Mark Raffeld; Stefania Pittaluga
Journal:  Am J Surg Pathol       Date:  2003-12       Impact factor: 6.394

8.  Cluster analysis and display of genome-wide expression patterns.

Authors:  M B Eisen; P T Spellman; P O Brown; D Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

9.  ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified.

Authors:  R L ten Berge; P C de Bruin; J J Oudejans; G J Ossenkoppele; P van der Valk; C J L M Meijer
Journal:  Histopathology       Date:  2003-11       Impact factor: 5.087

10.  The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells.

Authors:  H Stein; D Y Mason; J Gerdes; N O'Connor; J Wainscoat; G Pallesen; K Gatter; B Falini; G Delsol; H Lemke
Journal:  Blood       Date:  1985-10       Impact factor: 22.113

View more
  17 in total

1.  CD30-positive malignant lymphomas: time for a change of management?

Authors:  Andreas Engert
Journal:  Haematologica       Date:  2013-08       Impact factor: 9.941

2.  Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma.

Authors:  Javeed Iqbal; George Wright; Chao Wang; Andreas Rosenwald; Randy D Gascoyne; Dennis D Weisenburger; Timothy C Greiner; Lynette Smith; Shuangping Guo; Ryan A Wilcox; Bin Tean Teh; Soon Thye Lim; Soon Yong Tan; Lisa M Rimsza; Elaine S Jaffe; Elias Campo; Antonio Martinez; Jan Delabie; Rita M Braziel; James R Cook; Raymond R Tubbs; German Ott; Eva Geissinger; Philippe Gaulard; Pier Paolo Piccaluga; Stefano A Pileri; Wing Y Au; Shigeo Nakamura; Masao Seto; Francoise Berger; Laurence de Leval; Joseph M Connors; James Armitage; Julie Vose; Wing C Chan; Louis M Staudt
Journal:  Blood       Date:  2014-03-14       Impact factor: 22.113

3.  RHOA mutations in peripheral T cell lymphoma.

Authors:  Jan Cools
Journal:  Nat Genet       Date:  2014-04       Impact factor: 38.330

Review 4.  Expression patterns of the activator protein-1 (AP-1) family members in lymphoid neoplasms.

Authors:  Alexandra Papoudou-Bai; Eleftheria Hatzimichael; Alexandra Barbouti; Panagiotis Kanavaros
Journal:  Clin Exp Med       Date:  2016-09-06       Impact factor: 3.984

Review 5.  Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas.

Authors:  Zachary Braunstein; Miguel Ruiz; Walter Hanel; Polina Shindiapina; John C Reneau; Jonathan E Brammer
Journal:  J Pers Med       Date:  2022-06-13

Review 6.  A three-signal model of T-cell lymphoma pathogenesis.

Authors:  Ryan A Wilcox
Journal:  Am J Hematol       Date:  2015-11-17       Impact factor: 10.047

7.  ALK-transformed mature T lymphocytes restore early thymus progenitor features.

Authors:  Annabelle Congras; Coralie Hoareau-Aveilla; Nina Caillet; Marie Tosolini; Patrick Villarese; Agata Cieslak; Laura Rodriguez; Vahid Asnafi; Elisabeth Macintyre; Gerda Egger; Pierre Brousset; Laurence Lamant; Fabienne Meggetto
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

8.  Aggressive Subcutaneous Panniculitis-Like CD30+ Peripheral T-Cell Lymphoma with Diffuse EBER Expression.

Authors:  Amandeep Aneja; Raghava LevakaVeera; Viren Patel; Ashish Bains
Journal:  Case Rep Hematol       Date:  2014-07-20

9.  Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations.

Authors:  Annalisa Roberti; Maria Pamela Dobay; Bettina Bisig; David Vallois; Cloé Boéchat; Evripidis Lanitis; Brigitte Bouchindhomme; Marie-Cécile Parrens; Céline Bossard; Leticia Quintanilla-Martinez; Edoardo Missiaglia; Philippe Gaulard; Laurence de Leval
Journal:  Nat Commun       Date:  2016-09-07       Impact factor: 14.919

10.  Chronic T cell receptor stimulation unmasks NK receptor signaling in peripheral T cell lymphomas via epigenetic reprogramming.

Authors:  Sylvain Carras; Dimitri Chartoire; Sylvain Mareschal; Maël Heiblig; Antoine Marçais; Rémy Robinot; Mirjam Urb; Roxane M Pommier; Edith Julia; Amel Chebel; Aurélie Verney; Charlotte Bertheau; Emilie Bardel; Caroline Fezelot; Lucien Courtois; Camille Lours; Alyssa Bouska; Sunandini Sharma; Christine Lefebvre; Jean-Pierre Rouault; David Sibon; Anthony Ferrari; Javeed Iqbal; Laurence de Leval; Philippe Gaulard; Alexandra Traverse-Glehen; Pierre Sujobert; Mathieu Blery; Gilles Salles; Thierry Walzer; Emmanuel Bachy; Laurent Genestier
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.